Genicular Nerve Block in Chronic Knee Osteoarthritis
CompletedNot applicableNCT07174167
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The goal of this clinical trial is to evaluate whether genicular nerve block (GNB) is effective in reducing pain in patients with knee osteoarthritis. It will also assess the comparative efficacy of different injection protocols. The main questions it aims to answer are: Does genicular nerve block with corticosteroid and local anesthetic provide superior pain relief compared with local anesthetic alone or placebo? Are there differences in clinical outcomes between the three treatment groups? Researchers will compare three groups: GNB with corticosteroid plus local anesthetic GNB with local anesthetic alone Sham procedure with saline (placebo control) Participants will: Receive the assigned injection protocol in accordance with their group Be evaluated at baseline and scheduled follow-up visits for pain intensity and functional status Report their pain scores and functional limitations using standardized assessment tools
Study details
- Official title
- Effectiveness of Genicular Nerve Block on Pain and Disability in Chronic Knee Osteoarthritis: A Randomized Controlled Trial
- Conditions
- Gonarthrosis
- Primary
- Genicular Nerve Block
- Gonarthritis
- Interventions
- Drug: Genicular nerve block with prilocaine
- Drug: genicular nerve block with prilocaine and triamcinolone
- Drug: Sham injection
- Sponsor
- Haydarpasa Numune Training and Research Hospital
- Start date
- 2023-04-01
- Primary completion
- 2024-02-10
- Sex
- All
- Age range
- from 45 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Countries
- Turkey (Türkiye)
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * age between 45 and 75 * diagnosed with knee osteoarthritis (OA) according to the American College of Rheumatology (ACR) criteria * possessing a Kellgren-Lawrence radiological grade of 2-3 Exclusion Criteria: * any joint injection to the target knee in the past 3 months * physical therapy for the target knee within the last 3 months * previous knee surgery * inflammatory rheumatic diseases * active lumbar radiculopathy on the same side * neurological disorders (e.g., Alzheimer's or dementia) * uncontrolled cardiopulmonary diseases * pregnancy or lactation * obesity (body mass index \[BMI\] \>35) * presence of a pacemaker * active malignancy
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07174167